SCHEMBL27153239

SCHEMBL27153239

COC(=O)C(CO)NC(=O)C(CO[Si](C)(C)C(C)(C)C)NC(=O)c1csc(-c2ccc(OC)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.44
CDC25A P30304 1/20 0.41
CDC25B P30305 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.41
P2RY12 Q9H244 1/20 0.39
ALDH1A1 P00352 5/20 0.39
CHEK1 O14757 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
HPGDS O60760 1/20 0.38
LMNA P02545 4/20 0.38
GAA P10253 2/20 0.38
ALOX12 P18054 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
PREP P48147 1/20 0.37
FAP Q12884 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27153238 1.00 TLR7 (0.44) TLR7CDC25ACDC25BIRAK4P2RY12
SCHEMBL27138495 0.87 SREBF2 (0.39) IRAK4P2RY12HPGDSLMNAMAPT
SCHEMBL27153882 0.87 NPC1 (0.41) P2RY12ALDH1A1KDM4EHPGDSMAPT
SCHEMBL27153881 0.87 NPC1 (0.41) P2RY12ALDH1A1KDM4EHPGDSMAPT
SCHEMBL27138499 0.87 SREBF2 (0.39) IRAK4P2RY12HPGDSLMNAMAPT
SCHEMBL31364471 0.87 TLR7 (0.49) TLR7CDC25ACDC25BIRAK4P2RY12
SCHEMBL27154325 0.86 HDAC1 (0.39) P2RY12KDM4EHPGDSGAACYP1A2
SCHEMBL27154326 0.86 HDAC1 (0.39) P2RY12KDM4EHPGDSGAACYP1A2
SCHEMBL27106960 0.86 TLR7 (0.56) TLR7CDC25ACDC25BIRAK4P2RY12
SCHEMBL27106959 0.86 TLR7 (0.56) TLR7CDC25ACDC25BIRAK4P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 US disclosed
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES 2025-01-09 US disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 TLR7 3115/4885CDC25A 1349/4885CDC25B 1396/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 TLR7 3030/4885CDC25A 1280/4885CDC25B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.